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Abstract
Background: Lung health is a critical area for research in sub-Saharan Africa. The International Multidisciplinary
Programme to Address Lung Health and TB in Africa (IMPALA) is a collaborative programme that seeks to fill
evidence gaps to address high-burden lung health issues in Africa. In order to generate demand for and facilitate
use of IMPALA research by policy-makers and other decision-makers at the regional level, an analysis of regional
lung health policies and stakeholders will be undertaken to inform a programmatic strategy for policy engagement.
Methods and analysis: This analysis will be conducted in three phases. The first phase will be a rapid desk review
of regional lung health policies and stakeholders that seeks to understand the regional lung health policy
landscape, which issues are prioritised in existing regional policy, key regional actors, and opportunities for
engagement with key stakeholders. The second phase will be a rapid desk review of the scientific literature,
expanding on the work in the first phase by looking at the external factors that influence regional lung health
policy, the ways in which regional bodies influence policy at the national level, investments in lung health,
structures for discussion and advocacy, and the role of evidence at the regional level. The third phase will involve a
survey of IMPALA partners and researchers as well as interviews with key regional stakeholders to further shed light
on regional policies, including policy priorities and gaps, policy implementation status and challenges, stakeholders,
and platforms for engagement and promoting uptake of evidence.
Discussion: Health policy analysis provides insights into power dynamics and the political nature of the
prioritisation of health issues, which are often overlooked. In order to ensure the uptake of new knowledge and
evidence generated by IMPALA, it is important to consider these complex factors.
Keywords: Lung health policy, policy stakeholder analysis, Africa lung health, tuberculosis, non-communicable
diseases
Background: lung health in Africa
Globally, it is estimated that 1 billion people, the majority of
whom live in low- and middle-income countries, suffer from
acute and chronic respiratory conditions [1, 2]. The five
principal conditions that contribute to the global burden of
respiratory diseases are asthma, chronic obstructive pulmon-
ary disease, acute respiratory infections, tuberculosis (TB)
and lung cancer [1]. The estimated burden in sub-Saharan
Africa (SSA) is large and growing. For example, lower re-
spiratory tract infections are the single biggest cause of mor-
tality in SSA, killing almost 1 million Africans each year [3],
and the WHO Africa region accounts for one-quarter (25%)
of global TB cases and deaths [4, 5]. However, despite the
high morbidity and mortality associated with many lung dis-
eases, they are still likely to be “under-estimated, under-
diagnosed, under-treated as well as inadequately prevented”
[6]. There is an urgent need for lung health research in SSA
to address this evidence gap and support the design and
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implementation of evidence-informed prevention, diagnosis
and treatment interventions.
The International Multidisciplinary Programme to Address
Lung Health and TB in Africa
The International Multidisciplinary Programme to Ad-
dress Lung Health and TB in Africa (IMPALA) is a 4-year
collaborative programme led by the Liverpool School of
Tropical Medicine and funded by the United Kingdom
National Institute of Health Research that seeks to fill evi-
dence gaps to address high-burden lung health issues in
Africa, many of which lack sufficient funding and research
evidence. IMPALA comprises 22 research and advocacy
institutions, including partners in 10 African countries,
that has been intentionally constituted to span the WHO
Africa Region. It engages in multi-disciplinary collabora-
tive research across clinical and public health, applied so-
cial science, health systems, health economics and
modelling, policy, and implementation science disciplines
to produce implementable solutions to critical issues sur-
rounding lung health. The work focuses specifically on in-
tersections between non-communicable lung disease,
acute lung disease, air pollution and tobacco-related dis-
ease as well as how each of these interact with TB.
IMPALA’s Pathways to Impact component has the
overarching goal of creating demand for and enabling
the use of evidence generated through IMPALA in lung
health policy decisions, programmes and practice.
Among other activities, this will be achieved by identify-
ing the policy factors influencing the behaviours and en-
vironments that protect or harm lung health through
policy and stakeholder analyses at the regional level.
This analysis of policies and stakeholders will be inclu-
sive of the five regions of the African Union, including
North Africa. The regional analyses will then inform
the development and implementation of a compre-
hensive policy engagement and evidence uptake strat-
egy for IMPALA. The strategy will be a living
document that will be informed by three phases of
analysis and adapted as necessary throughout the life
of the programme.
Methodology and analysis
The study will be conducted in three phases as depicted
diagrammatically below.
Phase 1: rapid desk review of regional lung health
policies and stakeholders in SSA
This first phase of work seeks to answer the following
questions:
1 What regional policies exist to tackle lung health
challenges in the region?
2 What lung health issues are prioritised in these
policies? What lung health issues are not prioritised
in these policies?
3 Who are the main actors in lung health policy
development and advocacy at the regional level
(including donors)?
a What are their interests and roles?
b Where is there potential for IMPALA to
expand key actors’ involvement in lung health/
TB?
4 What opportunities exist for regional policy
engagement with key stakeholders?
Methodology
This analysis will draw from a rapid desk review of key
stakeholders in SSA as well as their lung health/TB pol-
icies, programmes and platforms. Platforms eligible for
inclusion should have content on decision-making, pol-
icy, experts, leaders, heads of state, ministries of health,
ministers, stakeholder engagement and evidence dissem-
ination. Relevant content will be added to the shared
Excel sheet.
Lung health and/or TB-specific organisations will be
identified through Google searches using the following
terms [Lung OR TB OR tuberculosis OR respiratory]
AND [chronic OR acute] AND [strategy OR policy OR
plan OR framework OR program* OR advoca* OR
organi* OR network OR fund] AND [Africa] AND [East*
OR South* OR West* OR Central]. Websites of the iden-
tified eligible organisations and of regional economic,
governance and public health bodies (e.g. African Union,
East Africa Community, Southern African Development
Community, Africa CDC) will be scanned to find policy
and programme documents/information related to TB/
lung health. Documents/information included in the re-
view and analysis will be those describing acute or
chronic lung health policies, strategies, frameworks, pro-
grammes and advocacy efforts. Documents/information
not focusing on lung health policies, plans, strategies,
frameworks, programmes and their implementation and
evaluation, and decision-making/advocacy platforms will
be excluded from the review. The organisations with
relevant TB/lung health policies and/or programmes will
be further reviewed to identify platforms for TB/lung
health-related policy engagement. In particular, re-
viewers will search the relevant organisations’ websites
and google with the following terms [conference OR
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technical working group OR TWG OR forum OR meet-
ing OR policy OR practice] AND [organisation name
OR organisation abbreviation]. The following content
will be extracted by two reviewers using an Excel sheet
shared between the reviewers: policy/programme/plat-
form name, date and aim; stakeholders involved, roles,
interests [developer(s), funder(s), implementer(s), target
population]; policy options, interventions or activities;
gaps and implementation challenges, including factors
influencing policy/programme design and implementa-
tion; and role of evidence.
Analysis
After data collection, four researchers will discuss the
content in the shared Excel sheet to reach consensus
on themes and trends in (1) lung health policies or
strategies at regional level; (2) lung health issue(s)
prioritised; (3) integration of lung health diseases with
other diseases/health issues; (4) key regional actors in
lung health policy development and advocacy; (5)
structures for discussing and advocating for lung
health policy; (6) factors that influence lung health
policies in Africa; (7) investment in lung health
programme implementation; and (8) the role of re-
search/evidence in lung health policy development,
implementation and advocacy.
Phase 2: rapid qualitative desk review of scientific
literature related to regional lung health policy
The second phase of work will seek to answer the fol-
lowing, in addition to expanding on the research ques-
tions from phase one:
1 What factors influence lung health policy in Africa
(or SSA)?
a What international, economic or cultural
factors influence regional policies, investments
and commitments to lung health?
b Are regional bodies influencing, in any way,
member country policies, investments and
commitments to lung health? For instance,
have they required specific action from
member countries to tackle lung health issues?
2 What investments are regional bodies currently
making in lung health? What investments are
needed by regional bodies to promote behaviours
and environments which protect lung health?
3 What structures are in place to facilitate discussion
and advocacy for lung health at regional level?
4 What is the role of evidence in addressing barriers
to promoting and sustaining behaviours and
environments that protect lung health at the
regional level?
Search strategy
The review will be limited to peer-reviewed articles and
grey literature published between 2008 and 2020. The
following search terms will be applied: [Lung OR re-
spiratory] AND [disease OR illness OR infection] AND
[chronic OR acute] OR [TB OR tuberculosis OR chronic
obstructive pulmonary disease OR COPD OR asthma
OR acute respiratory infection* OR pneumonia OR se-
vere acute respiratory syndrome OR respiratory syncytial
virus OR RSV] AND [policy OR strategy OR program*
OR advocacy] AND [policymak* OR practi* OR stake-
holder*] AND [Africa] AND [East* OR South* OR West*
OR Central*]. HINARI, JSTOR, Google Scholar and
websites of organisations focusing on lung health policy,
programmes and advocacy will be used to search for
peer-reviewed and grey literature.
Inclusion criteria
Scientific articles will be eligible for inclusion if they
focus on acute or chronic lung health policy, programme
and strategy development, implementation or advocacy,
including content and implementation gaps and chal-
lenges, and the role of evidence in acute or chronic lung
health policy and programme development and imple-
mentation. Articles not focusing on lung health from the
perspective of policy development and implementation
and those in languages other than English will be
excluded.
Screening
After removal of duplicates, abstracts of retrieved articles
will be screened against the inclusion and exclusion cri-
teria. Subsequently, remaining papers will be read in full
and screened against the inclusion and exclusion criteria.
Papers shall be shared between and reviewed by two re-
viewers using an Excel spreadsheet that, as in phase one,
details any policies, programmes or interventions, date
and aim, involved stakeholders and their interests, and
policy and programme gaps, challenges and options. Pa-
pers retained by both reviewers after the first round of
screening will then be reviewed by a third reviewer. Dif-
ferences will be discussed between the three reviewers
until consensus is reached.
Analysis
The reviewers will sort the selected papers by theme in-
dividually, and then come together to discuss any incon-
sistencies. Once consensus is reached, the researchers
will generate a narrative synthesis based on their discus-
sions. This will summarise emergent themes and pat-
terns in the main findings of the studies to address each
research question, including the factors influencing lung
health policy in Africa, investments by regional bodies,
regional decision-making and advocacy platforms, and
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the role of evidence. This will be used to develop a draft
policy engagement strategy for the programme that pro-
vides evidence-based detail on regional lung health pol-
icies, actors, issues, structures, barriers and
opportunities, guided by the Overseas Development In-
stitute’s Rapid Outcome Mapping Approach [7].
Phase 3: survey of IMPALA lung health experts and
interview of key regional stakeholders
The third phase will generate empirical evidence to sup-
plement the evidence from Phases 1 and 2 using an on-
line qualitative survey and in-depth interviews. A
synopsis of the findings from Phases 1 and 2, including a
draft policy engagement strategy for the programme, will
be shared with IMPALA partners and researchers, along
with a survey designed to allow participants to confirm
or suggest modifications to the emerging engagement
strategy, including about key regional long health pol-
icies, policy priorities, gaps and implementation chal-
lenges. This will also ask IMPALA partners and
researchers about their and other stakeholders’ involve-
ment in regional policy development and implementa-
tion, advocacy and research, including their interests and
power to influence change and key decision-making
platforms for lung health. Key stakeholders with expert-
ise in lung health policy in Africa identified from the
survey will be interviewed to obtain additional insights
on influencers of lung health policy in Africa to ensure
the strategy is well-designed and directed. An interview
guide will be used to conduct the interviews and its de-
sign will draw on the findings of the previous phases in
order to elaborate upon themes identified and any evi-
dence gaps.
Sampling
The survey will be administered to 5 research
programme leads, 11 country leads, 5 PhD students and
5 post-doctoral research associates. Purposive sampling
will be performed and interviews will be conducted with
approximately 10–15 key stakeholders, including policy-
makers, implementers and funders, with expertise in
lung health policy in Africa.
Data collection and analysis
Survey Monkey will be used to gather the survey data,
manage the survey dataset and conduct data analysis.
Additional analysis may be conducted in Excel or NVivo
as needed. Responses to open-ended survey questions
will be post-coded to be transformed into quantitative
data. Themes will be discussed between two researchers
until consensus is reached. Descriptive analysis will be
used to analyse the data by survey question.
Key informant interviews will be conducted by two
researchers face-to-face or online via Bluejeans,
GoToMeeting or Skype, dependent on the researchers
and interviewees’ locations. The interviews will be
semi-structured and designed to last approximately
45 minutes. The researchers will receive written con-
sent as hard or soft copy as well as oral consent to
record the interview. The interviews will be tran-
scribed and coded by two researchers who will dis-
cuss emergent themes until consensus is met.
Descriptive analysis will be used to analyse the inter-
view findings, manually or using NVivo, as needed.
This analysis will inform revisions to the IMPALA
policy engagement strategy.
Ethics
Ethical approval will be sought from Liverpool School of
Tropical Medicine and the National Health Science Re-
search Committee in Malawi.
Discussion
There have long been calls to extend the use of health pol-
icy analysis in low- and middle-income countries as litera-
ture has shown the importance of incorporating “politics,
process and power” into studies involving health policy and
systems [8–10]. This is because health policy analysis can
meet health aims by showing why some health issues re-
ceive more attention than others, identifying barriers in im-
plementation and identifying stakeholder positions on
health issues, which can be used to develop strategies to ad-
vance reforms [11]. To inform IMPALA’s regional policy
engagement, research uptake and accountability strategy,
the regional lung health policy and stakeholder analysis
seeks to generate an understanding of such essential issues
within the landscape in which IMPALA is operating.
The methods outlined and the findings they yield are well
positioned to achieve this objective. Each phase of the ana-
lysis, by design, builds on the foundation of the previous
phase in order to contextualise findings. Specifically, the
first phase will provide a general picture of regional support
and investment in the various lung health illnesses by iden-
tifying key policies and actors as well as stakeholders’ rele-
vant programmes and platforms. The second phase will
then shed light on the drivers of the findings in Phase 1 by
looking at the literature on different lung health issues. Fi-
nally, the third phase will bring findings from Phases 1 and
2 to life by explaining the unwritten and informal know-
ledge around lung health policy in Africa.
Beyond filling a major evidence gap on lung health
policy in Africa, the analysis findings are critical if the
research generated in IMPALA is to have influence be-
yond academia. Ultimately, the generated evidence will
identify key lung health stakeholders, policies and plat-
forms that IMPALA should leverage to maximise the
policy impact of the multidisciplinary lung health re-
search generated through the programme.
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